Compare AdaptHealth Corp (AHCO) vs McKesson Corporation (MCK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AdaptHealth Corp vs McKesson Corporation — how do they compare? AdaptHealth Corp trades at $10.04 (market cap $1.38B), while McKesson Corporation trades at $817.45 (market cap $94.52B). The key difference: McKesson Corporation is far larger — about 68.5× AdaptHealth Corp's market cap, and McKesson Corporation pays a 0.41% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | MCK | |
|---|---|---|
Market Cap | $1.38B | $94.52B |
Sector | Health | Health |
52-Week High | $13.38 | $995.69 |
52-Week Low | $8.68 | $659.01 |
Enterprise Value | $3.33B | $99.16B |
Dividend Yield | — | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.
The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.
McKesson (MCK) trades at $807.33, up 2.67% with strong bullish momentum. The stock shows robust fundamentals with consistent earnings beats and revenue growth from $309B to $359B in 2025. Technical indicators signal bullish momentum with price above key support levels. Recent news highlights McKesson's growth in specialty pharma and oncology services, supported by positive analyst sentiment.
Outlook remains positive with 80% analyst buy ratings and $932.83 consensus price target, offering 15% upside. Risks include policy pressures and margin compression, but diversified portfolio and investment-grade rating provide stability. Earnings momentum and strategic investments position MCK for continued growth in healthcare distribution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AdaptHealth Corp
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
